PHARMACY

AACP, NCPA sponsor contest to spawn best practices on adherence education

BY Michael Johnsen

ALEXANDRIA, Va. — The American Association of Colleges of Pharmacy and the National Community Pharmacists Association are focusing on the issue of medication adherence with the announcement of a joint pharmacy educators challenge and half-day symposium that will highlight the best practices in teaching medication adherence.
 
The Medication Adherence Educators Challenge is the first effort of its kind and is aimed at better understanding the resources and teaching strategies currently being utilized to prepare student pharmacists to detect, monitor and improve medication adherence in pharmacy practice. It calls upon schools to submit their teaching tools in the area of medication adherence, including tools currently used in the curriculum and experiential learning, as well as ideas and concepts still in development.
 
“This challenge and symposium provide an unprecedented opportunity for faculty members to share their medication adherence education tools, as well as to strategically think about innovative teaching methods that could be utilized by academic pharmacy and other health professions in the future,” AACP EVP and CEO Lucinda Maine said.
 
The three challenge categories include didactic, laboratory and experiential educational teaching tools, with consideration given to entries designed to assist students in planning and applying an adherence intervention strategy. The submissions will be judged by representatives from AACP and NCPA. Three submissions will be chosen as the challenge winners. Each winning school will receive a $1,000 award, and each submitting author will receive a $500 honorarium.

The deadline for challenge entries is March 30. More information about the challenge, including the submission guidelines, may be found on the AACP website. A symposium agenda as well as pre-registration for the symposium will be available in May 2012, the association said.
 
The most innovative tools will be presented as part of a joint AACP-NCPA Medication Adherence Educators Symposium on July 18 in Kissimmee, Fla. The half-day symposium dedicated to adherence teaching will be held in conjunction with AACP’s 2012 Annual Meeting at the Gaylord Palms Resort, and will provide pharmacy faculty members the chance to share best practices, resources, and teaching strategies currently being used to teach medication adherence.
 
In addition to working with AACP, NCPA recently launched Simplify My Meds, a personalized coordinated refill program that facilitates improved adherence by aligning a patient’s prescriptions to be filled on the same day each month. The model decreases regimen complexity and reduces the risk of gaps in therapy.
 
NCPA and AACP also are committed partners of the National Consumers League’s Script Your Future campaign, a public education campaign to raise awareness among patients about the consequences of not taking medication as directed. AACP recently co-sponsored the Script Your Future Medication Adherence Challenge, which engaged student pharmacists in raising public awareness about medication adherence.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mylan receives tentative approval for HIV/AIDS drug in developing countries

BY Alaric DeArment

PITTSBURGH — The Food and Drug Administration has given tentative approval to a division of Mylan for a generic drug for treating HIV and AIDS in children in developing countries.

Mylan said Thursday that the FDA had tentatively approved Mylan Labs’ abacavir sulfate and lamivudine tablets in the 60 mg/30 mg strength. The drug is a generic version of Viiv Healthcare’s Epzicom and was approved under the President’s Emergency Plan for AIDS Relief. The drug will only be available for purchase in certain developing countries outside the United States.

"The approval of abacavir sulfate and lamivudine further supports Mylan’s mission to continue expanding access to high-quality medicine around the world, which is especially crucial for children living with HIV/AIDS," Mylan CEO Heather Bresch said. "This product combines two medications in one tablet, which may support treatment adherence in children as it reduces the pill burden often associated with complex antiretroviral regimens."

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mylan’s Tony Mauro elected as GPhA chairman

BY Alaric DeArment

WASHINGTON — The president of one of the world’s largest generic drug manufacturers will serve as chairman of the Generic Pharmaceutical Association, the organization said Thursday.

The GPhA announced that it had elected Mylan president Tony Mauro as chairman. Mauro previously served as the organization’s vice chairman. "With growing populations, economic recessions and increasing healthcare costs, the need for widespread access to more affordable medicine has never been so great," Mauro said. "The generic pharmaceutical industry is stronger than it has ever been, and I see tremendous opportunities ahead for our association and for our industry."

Meanwhile, Sandoz president and CEO Don DeGolyer was elected vice chairman, while Momenta Pharmaceuticals president Craig Wheeler was reelected as secretary treasurer. Other board members include:

  • Debra Barrett, SVP government and public affairs, Teva Pharmaceuticals;
  • Carole Ben-Maimon, president of global pharmaceuticals, Impax Labs;
  • Paul Bisaro, president and CEO, Watson Pharmaceuticals;
  • Doug Boothe, president and CEO, Actavis;
  • Chuck Caprariello, VP corporate communications and government affairs, Ranbaxy;
  • Don DeGolyer, president and CEO, Sandoz;
  • John Ducker, president and CEO, APP Pharmaceuticals;
  • Jeffrey Glazer, CEO, Heritage Pharmaceuticals;
  • David Klaum, SVP and GM, Fougera;
  • Thomas Moore, president, U.S., Hospira; and
  • Joseph Renner, president and CEO, Zydus Pharmaceuticals USA.

Mauro, DeGolyer, Wheeler, Barrett, Ben-Maimon, Bisaro, Boothe, Caprariello and Moore will serve on the GPhA executive committee.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES